ClinicalTrials.Veeva

Menu

CP1110 Sound Processor Feasibility

Cochlear logo

Cochlear

Status

Completed

Conditions

Adult Cochlear Implant Recipients

Treatments

Device: CP1000
Device: CP1110

Study type

Interventional

Funder types

Industry

Identifiers

NCT04898673
CLTD5804

Details and patient eligibility

About

The clinical study aims to investigate the speech performance with the CP1110 Sound Processor, compared with the CP1000 Sound Processor, and inclusion of a noise reduction feature in the Automatic Scene Classifier..

Full description

The study will build on the evidence previously collected on behind-the-ear sound processors and noise reduction, with particular focus on the speech perception performance of the CP1110 Sound Processor when compared to the CP1000 Sound Processor.

To assess the primary and secondary speech perception objectives, the study incorporates a within-subject repeated-measures design in which each subject will undergo in-booth speech perception testing with all combinations of hardware and signal processing settings in a sound booth. The average difference scores will indicate the performance difference for each of the paired comparisons.

Enrollment

21 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Aged 18 years or older
  2. Post lingually deafened
  3. Implanted with the CI600 Series (CI612, CI632, CI622, CI624), CI500 Series (CI512, CI532, CI522) or Freedom Series (CI24RE(CA), CI24RE(ST), CI422)
  4. At least 6 months experience with a cochlear implant.
  5. At least 3 months experience with a Nucleus 6 (CP910/920), Kanso (CP950), Kanso 2 (CP1150) or Nucleus 7 (CP1000) Sound Processor
  6. Able to score 30% or more at +15 SNR with CI alone on a sentence in babble test
  7. Willingness to participate in and to comply with all requirements of the protocol.
  8. Fluent speaker in English as determined by the investigator
  9. Willing and able to provide written informed consent

Exclusion criteria

  1. Additional disabilities that would prevent participation in evaluations.
  2. Unrealistic expectations on the part of the subject, regarding the possible benefits, risks and limitations that are inherent to the procedures.
  3. Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator.
  4. Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling.
  5. Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of this investigation.
  6. Currently participating, or participated in another interventional clinical study/trial in the past 30 days, or (if less than 30 days) the prior investigation was Cochlear sponsored and determined by the investigator to not impact clinical findings of this investigation.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

21 participants in 2 patient groups

CP1000 Sound Processor followed by the CP1110 Sound Processor
Experimental group
Description:
All study subjects were provided with a unique identifier. The ones that ended in an odd number were administered the CP1000 Sound Processor followed by the CP1110 Sound Processor.
Treatment:
Device: CP1000
Device: CP1110
CP1110 Sound Processor followed by the CP1000 Sound Processor
Experimental group
Description:
All study subjects were provided with a unique identifier. The ones that ended in an even number were administered the CP1110 Sound Processor followed by the CP1000 Sound Processor.
Treatment:
Device: CP1000
Device: CP1110

Trial documents
2

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems